Novartis Shifts Clinical Trials to Emerging Markets, HB Reports
By -
Sep 12, 2012
Novartis AG (NOVN) is shifting more of its clinical trials to emerging market regions such as Asia-Pacific, the Middle East and Africa, Handelsblatt reported, citing Novartis information.
The number of clinical trials rose to 44 percent of all of Novartis trials, not including trials of cancer drugs, the newspaper reported.
To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net